Medtech regains some strength
VC funding in medtech skyrocketed to $19.7 billion in 2021 before plummeting, and funding this year could remain moderately below 2022’s levels.
According to PitchBook’s Q2 2023 Medtech Report, deal activity in the sector has increased since Q1, and an increased variety of medtech categories—including surgical robotics, cancer care, and neurostimulation—received $100 million-plus VC deals. VCs are also intrigued by new technologies related to precision medicine, treatment for sleep disorders, and mixed reality surgical navigation. And with improved hospital margins and robust patient interest in elective surgeries, the prognosis is good for investors to return to the space.
Table of contents
| Vertical update | 3 |
| Q2 2023 timeline | 4 |
| Medtech landscape | 5 |
| Medtech VC and PE ecosystem market map | 6 |
| VC and PE activity | 8 |
| Emerging opportunities | 12 |
| Mixed reality surgical navigation | 13 |
| Solving sleep apnea | 15 |
| Select company highlights | 17 |
| BillionToOne | 18 |
| AliveCor | 20 |
| Appendix | 22 |